Entrada receives UK authorization for Phase 1/2 trial of ENTR-601-45 in DMD exon 45 skipping

Entrada Therapeutics, Inc.

UK MHRA and Research Ethics Committee clearance to start ELEVATE-45-201, a Phase 1/2 MAD study of ENTR-601-45.
On track to initiate the trial in Q3 2025; Part A will evaluate doses 5–15 mg/kg every 6 weeks in ~24 patients.
Second Duchenne program (after ELEVATE-44); regulatory filings also submitted in the EU with review ongoing.
Study is randomized, double-blind, placebo-controlled with a Part B for optimal dose evaluation and an OLE.
CEO states strategy to run UK/EU studies first, then share data with FDA to enable U.S. registrational studies.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.